In a bid to strengthen its epilepsy pipeline, UCB has agreed to acquire rare disease drug developer, Zogenix, for US$26 per share which represents a total transaction value of US$1.9 B. The deal provides UCB access to Zogenix’s key product, Fintepla, which is used in the treatment of seizures associated with Dravet syndrome. Interestingly, the deal comes only a few months before the expirations of the US patent of UCB’s blockbuster epilepsy drug, Vimpat.